LAE002 Plus Phase III protocol approval for LAE001 comes as a result of positive Phase II data showing promising benefits in patients with metastatic castration-resistant prostate cancer (mCRPC).
FDA Approves Phase 3 Study Protocol for Laekna’s LAE002 in Combination with LAE001 for the Treatment of Prostate Cancer
Leave a comment
